Key Takeaways VCYT is advancing its nasal swab NIGHTINGALE study and MRD platform for multi-tumor diagnostics. VCYT's Decipher test volumes rose 37% in Q1, with 85 studies backing its role in prostate cancer care. Veracyte is grappling with falling Biopharma revenues and cost pressures from macroeconomic headwinds.Veracyte (VCYT) is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The company’s Decipher franchise continues to be a strong tailwind, ...

Acuity (AYI) Q3 2025 Earnings Call June 26, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Acuity Fiscal twenty twenty five Third Quarter Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, the company will conduct a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Charlotte McLaughlin, Vice President of Investor Relations. Charlotte, please go ahead. Sp ...